Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

Yi, Chenhe, Chen, Lirong, Lin, Zhifei, Liu, Lu, Shao, Weiqing, Zhang, Rui, Lin, Jing, Zhang, Jubo, Zhu, Wenwei, Jia, Huliang, Qin, Lunxiu, Lu, Lu, Chen, Jinhong·2021·Hepatology

Abstract

Background and Aims: Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection. Approach and Results: First, in patients with HCC, lenvatinib‐treated recurrent tumors had lower programmed death ligand 1 (PD‐L1) expression and regulatory T cell (Treg) infiltration compared with matched primary tumors. Consistently, in C57BL/6 wild‐type mice receiving anti–programmed cell death 1 (PD‐1) therapy, PD‐L1 expression and Treg infiltration in s.c. tumors were reduced when adding lenvatinib to the scheme. Mechanistically, on the one hand, FGF receptor 4 (FGFR4) was the most pivotal target in PD‐L1 down‐regulation by lenvatinib in vitro. Furthermore, lenvatinib reinforced the proteasomal degradation of PD‐L1 by blocking the FGFR4–glycogen synthase kinase 3β axis and rescued the sensitivity of interferon‐γ‐pretreated HCC cells to T‐cell killing by targeting FGFR4. On the other hand, the level of IL‐2 increased after anti‐PD‐1 treatment, but IL‐2‐mediated Treg differentiation was blocked by lenvatinib through targeting FGFR4 to restrain signal transducer and activator of transcription 5 (STAT5) phosphorylation. By regulating the variations in the number of Tregs and the tumor FGFR4 level in C57BL/6–forkhead box protein P3 (Foxp3DTR ) mice, we found that high levels of FGFR4 and Treg infiltration sensitized tumors to the combination treatment. Finally, high levels of FGFR4 and Foxp3 conferred immune tolerance but better response to the combined therapy in patient cohorts. Conclusions: Lenvatinib reduced tumor PD‐L1 level and Treg differentiation to improve anti‐PD‐1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti‐PD‐1 combination therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.31921

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 295

Metadata

Authors
Yi, C., Chen, L., Lin, Z., Liu, L., Shao, W., Zhang, R., Lin, J., Zhang, J., Zhu, W., Jia, H., Qin, L., Lu, L., & Chen, J.
Venue
Hepatology
Published
2021-08-25
Volume
74
Issue
5
Pages
2544-2560
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W3165017392
Cited by
295
References
41
FWCI
17.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC. https://app.cochat.ai/papers/10.1002/hep.31921
The paper
Yi, C., Chen, L., Lin, Z., Liu, L., Shao, W., Zhang, R., Lin, J., Zhang, J., Zhu, W., Jia, H., Qin, L., Lu, L., & Chen, J. (2021). Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC. Hepatology. https://doi.org/10.1002/hep.31921

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.